TaiMed Biologics Inc. (TPEX:4147)
Taiwan · Delayed Price · Currency is TWD 64.90
+2.20 (3.51%)
Sep 8, 2026, 12:50 PM CST
TaiMed Biologics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 619.49 | 611.35 | 610.16 | 491.78 | 563.01 | 413.44 | |
Revenue Growth | 3.58% | 0.19% | 24.07% | -12.65% | 36.18% | -42.77% |
Cost of Revenue | 335.94 | 351.9 | 398.94 | 266.54 | 347.3 | 329.49 |
Gross Profit | 283.54 | 259.45 | 211.23 | 225.23 | 215.71 | 83.96 |
Selling, General & Admin | 73.07 | 72.26 | 75.29 | 97.19 | 74.45 | 109.72 |
Research & Development | 398.01 | 381.84 | 388.21 | 294.28 | 333.12 | 460.6 |
Operating Expenses | 471.08 | 454.1 | 463.49 | 391.46 | 407.57 | 570.32 |
Operating Income | -187.53 | -194.65 | -252.27 | -166.23 | -191.86 | -486.37 |
Interest Expense | -10.4 | -10.71 | -12.6 | -14.81 | -10.1 | -7.44 |
Interest & Investment Income | 30.28 | 28.94 | 33.97 | 8.46 | 4.34 | 4.03 |
Currency Exchange Gain (Loss) | 25.15 | 6.49 | 26.35 | 2.04 | 48.69 | -11.38 |
Other Non Operating Income (Expenses) | 3.9 | 4.46 | 5.05 | 4.78 | 2.44 | 3.45 |
EBT Excluding Unusual Items | -138.6 | -165.48 | -199.51 | -165.76 | -146.48 | -497.7 |
Gain (Loss) on Sale of Investments | 1.28 | -0.69 | - | -29.05 | -122.81 | 26.76 |
Gain (Loss) on Sale of Assets | -1.58 | -1.61 | -2.32 | - | - | 0.01 |
Pretax Income | -138.9 | -167.78 | -201.83 | -194.81 | -269.29 | -470.93 |
Net Income | -138.9 | -167.78 | -201.83 | -194.81 | -269.29 | -470.93 |
Net Income to Common | -138.9 | -167.78 | -201.83 | -194.81 | -269.29 | -470.93 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 273 | 273 | 268 | 253 | 252 | 252 |
Shares Outstanding (Diluted) | 273 | 273 | 268 | 253 | 252 | 252 |
Shares Change | -0.22% | 1.85% | 6.08% | 0.18% | 0.04% | 0.03% |
EPS (Basic) | -0.51 | -0.61 | -0.75 | -0.77 | -1.07 | -1.87 |
EPS (Diluted) | -0.51 | -0.61 | -0.75 | -0.77 | -1.07 | -1.87 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 108.01 | 168.48 | -387.61 | -31.75 | -608.77 | -220.96 |
Free Cash Flow Per Share | 0.40 | 0.62 | -1.45 | -0.13 | -2.41 | -0.88 |
Gross Margin | 45.77% | 42.44% | 34.62% | 45.80% | 38.31% | 20.31% |
Operating Margin | -30.27% | -31.84% | -41.34% | -33.80% | -34.08% | -117.64% |
Profit Margin | -22.42% | -27.44% | -33.08% | -39.61% | -47.83% | -113.90% |
Free Cash Flow Margin | 17.44% | 27.56% | -63.52% | -6.46% | -108.13% | -53.44% |
EBITDA | -39.09 | -46.5 | -104.49 | -17.72 | -42.22 | -336.3 |
EBITDA Margin | -6.31% | -7.61% | -17.13% | -3.60% | -7.50% | -81.34% |
D&A For EBITDA | 148.44 | 148.15 | 147.78 | 148.51 | 149.64 | 150.07 |
EBIT | -187.53 | -194.65 | -252.27 | -166.23 | -191.86 | -486.37 |
EBIT Margin | -30.27% | -31.84% | -41.34% | -33.80% | -34.08% | -117.64% |